By Adam Clark

Shield Therapeutics PLC (STX.LN) said Monday that Teva Pharmaceutical Industries Ltd. (TEVA) has filed a notice of appeal against the recent grant of a European patent for Shield's Feraccru iron-deficiency treatment.

Shield said Teva opposed its patent covering a "process for preparing an iron hydroxypyrone."

No data has been set for the hearing. Shield said it will defend its intellectual property.

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

(END) Dow Jones Newswires

June 03, 2019 03:12 ET (07:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Shield Therapeutics Charts.
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Shield Therapeutics Charts.